Cell Reports Medicine, Год журнала: 2023, Номер 4(11), С. 101293 - 101293
Опубликована: Ноя. 1, 2023
In this issue, Pang and colleagues
Язык: Английский
Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)
Опубликована: Май 8, 2024
Abstract Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, exploration of emerging modalities such as immunotherapy integration medicine engineering technology therapy, efficacy these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny inhibitory milieu within GBM has underscored significance cellular constituents microenvironment their interactions with cells neurons. Novel immune targeted therapy strategies have emerged, offering promising avenues for advancing treatment. One pivotal mechanism orchestrating immunosuppression involves aggregation myeloid-derived suppressor (MDSCs), glioma-associated macrophage/microglia (GAM), regulatory T (Tregs). Among these, MDSCs, though constituting minority (4–8%) CD45 + GBM, play central component fostering evasion propelling tumor progression, angiogenesis, invasion, metastasis. MDSCs deploy intricate mechanisms that adapt dynamic (TME). Understanding interplay between provides compelling basis This review seeks elucidate inherent explore existing targets, consolidate insights into MDSC induction contribution immunosuppression. Additionally, comprehensively surveys ongoing clinical trials potential strategies, envisioning future where targeting could reshape landscape GBM. Through synergistic other modalities, this approach can establish multidisciplinary, multi-target paradigm, ultimately improving prognosis quality life patients
Язык: Английский
Процитировано
60
Cellular and Molecular Immunology, Год журнала: 2024, Номер 21(12), С. 1354 - 1375
Опубликована: Окт. 15, 2024
Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard care offers minimal clinical benefit, most GBM patients experience recurrence after treatment. In recent years, significant advancements have been made the development novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance many advanced cancers. However, benefit immune-based treatments limited because unique immune profiles, cell heterogeneity, immunosuppressive microenvironment. this review, we present a detailed overview current immunotherapeutic discuss challenges potential molecular mechanisms underlying GBM. Furthermore, provide in-depth discussion regarding GBM, which will likely require combination therapies.
Язык: Английский
Процитировано
21
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Июнь 26, 2024
Glioblastoma (GBM) tumors are the most aggressive primary brain in adults that, despite maximum treatment, carry a dismal prognosis. GBM exhibit tissue hypoxia, which promotes tumor aggressiveness and maintenance of glioma stem cells creates an overall immunosuppressive landscape. This article reviews how hypoxic conditions overlap with inflammatory responses, favoring proliferation inhibiting cytotoxic T cell development. Immunotherapies, including vaccines, immune checkpoint inhibitors, CAR-T therapy, represent promising avenues for treatment. However, challenges such as heterogeneity, TME, BBB restrictiveness hinder their effectiveness. Strategies to address these challenges, combination therapies targeting actively being explored improve outcomes patients. Targeting hypoxia immunotherapy represents potential strategy enhance treatment efficacy.
Язык: Английский
Процитировано
11
Biomaterials, Год журнала: 2024, Номер 311, С. 122694 - 122694
Опубликована: Июнь 28, 2024
Язык: Английский
Процитировано
8
Trends in Molecular Medicine, Год журнала: 2024, Номер 30(5), С. 429 - 442
Опубликована: Март 7, 2024
Glioma is a type of aggressive and incurable brain tumor. Patients with glioma are highly resistant to all types therapies, including immunotherapies. Epigenetic reprogramming key molecular hallmark in tumors across cancer types, glioma. Mounting evidence highlights pivotal role epigenetic regulation shaping tumor biology therapeutic responses through mechanisms involving both cells immune cells, as well their symbiotic interactions the microenvironment (TME). In this review, we discuss that impacts cell immunity cell-autonomous non-cell-autonomous manner. Moreover, provide an overview potential approaches can disrupt epigenetic-regulated tumor-immune symbiosis TME.
Язык: Английский
Процитировано
6
Cell Reports Medicine, Год журнала: 2024, Номер unknown, С. 101806 - 101806
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
6
Cancers, Год журнала: 2024, Номер 16(11), С. 2089 - 2089
Опубликована: Май 30, 2024
Background: The study aims to investigate the role of hypoxia-inducible factors (HIFs) in development, progression, and therapeutic potential glioblastomas. Methodology: study, following PRISMA guidelines, systematically examined hypoxia HIFs glioblastoma using MEDLINE (PubMed), Web Science, Scopus. A total 104 relevant studies underwent data extraction. Results: Among studies, global contributions were diverse, with China leading at 23.1%. most productive year was 2019, accounting for 11.5%. Hypoxia-inducible factor 1 alpha (HIF1α) frequently studied, followed by 2 (HIF2α), osteopontin, cavolin-1. Commonly associated pathways include glucose transporter (GLUT1) 3 (GLUT3) receptors, vascular endothelial growth (VEGF), phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target rapamycin (mTOR) pathway, reactive oxygen species (ROS). HIF expression correlates various hallmarks, including survival, neovascularization, metabolism, migration, invasion. Conclusion: Overcoming challenges such as treatment resistance absence biomarkers is critical effective integration HIF-related therapies into aim optimizing patient outcomes.
Язык: Английский
Процитировано
5
International Journal of Biological Macromolecules, Год журнала: 2024, Номер 268, С. 131892 - 131892
Опубликована: Апрель 25, 2024
Язык: Английский
Процитировано
4
Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)
Опубликована: Авг. 3, 2024
An increasing number of clinical studies have begun to explore combination strategies with immune checkpoint inhibitors, aiming present new opportunities for overcoming anti-PD-1 treatment resistance in gastric cancer. Unfortunately, the exploration certain inhibitor has yielded suboptimal results. Therefore, it is necessary comprehensively analyze expression patterns checkpoints and identify optimal regimens inhibitors other inhibitors.
Язык: Английский
Процитировано
4
Biomarker Research, Год журнала: 2024, Номер 12(1)
Опубликована: Окт. 7, 2024
Abstract Background Glioma is the most common primary malignant tumor in brain, and even with standard treatments including surgical resection, radiotherapy, chemotherapy, long-term survival rate of patients remains unsatisfactory. Recurrence one leading causes death glioma patients. The molecular mechanisms underlying recurrence remain unclear. Methods Our study utilized single-cell sequencing, spatial transcriptomics, RNA-seq data to identify a subtype FN1 + tumor-associated macrophages (FN1 TAMs) associated recurrence. Results This revealed an increased abundance TAMs recurrent gliomas, indicating their potential involvement as critical factor A negative correlation was observed between gliomas interval time recurrence, suggesting poor prognosis for high levels TAMs. Further investigation showed that were enriched hypoxic regions, implying metabolic changes tumors drive production recruitment Additionally, found contribute regulation immunosuppressive microenvironment might serve indicator patients’ sensitivity immunotherapy. Finally, we developed user-friendly website, PRIMEG ( http://www.szflab.site/PRIMEG/ ), exploring immune gliomas. Conclusion findings highlight providing new insights into therapeutic targets. Moreover, hold promise predicting therapy response aiding more precise risk stratification
Язык: Английский
Процитировано
4